Microsoft word - growmx.doc
Synergistically Advanced Creatine Monohydrate Formula
Page 1 of 3 (references on back) NOTE: This email may contain PRIVILEGED and CONFIDENTIAL information and is intended only for the use of the specific individual(s) to which it is addressed. If you are not either an
intended recipient of this email, or the person responsible for printing and/or delivering this message to its intended recipient, then you are hereby notified that any unauthorized use,
dissemination or copying of this email or the information contained in it or attached to it is strictly prohibited. If you have received this email in error, then please delete it and immediately notify
the person named above by return mail. Unless a contrary intention is clearly stated in the body of the message transmitted herewith, this email does not constitute an election by its sender to
transact business by electronic means.
J is the most advanced stack of anabolic and anti-catabolic nutrients ever assembled into one
capsule. Contrary to popular belief, human bodies grow bigger, thicker and denser outside of the weight room,
not in (this does not mean without excersise). Designed to help maximize growth from serious training, GROWTH MAXJ
should take bodybuilding nutrition to the next level by combing the cell-volumizing effects of
creatine with nine other essential and key synergistic ingredients, including tribulus,
DHEA1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36, glutamine1,2, NAC, BCAA's and acetyl-L-
Carnitine1,2,3,4,5,6,7,8,9,10. Damaged muscle fibers need time to recover, repair themselves and heal. That's how the
human body and muscle tissue develop. Serious over-training leads to muscle wasting. *GROWTH MAXJ
should improve the development of your muscles by energizing your muscles with the above nutrients and
blasting your body with pro-anabolic synergistic nutrients. For the next generation of explosive creatine
monohydrate advancement technology, try GROWTH MAXJ.
Why choose USA SPORTS LABS GROWTH MAXJ
- USA LABORATORIES
processing, which is Pure Nutriceutical Processing, provides:
Υ Higher quality than others can attempt to afford
Υ Combined cell-volumizing effectiveness
Υ Explosive synergistic ingredient combination
Thousands of studies have been published regarding creatine, now the second generation of creatine advancement is here. Nutritional Facts: Serving Size: 10 Capsules
DHEA (Dehydroeplandrosterone) .60 mg * *
Zinc .15 mg * * *% Daily value ** Not currently considered essential
: As a dietary supplement, take 5 capsules twice daily with meals or as directed by your health care professional.
Athletes, male or female, teenage years and above: not limited to cancer patients or other physically
Creatine Monohydrate, Pro-Mass, DHEA, Amino Acids
No others are available with exclusive P.N.P. processing.
Available in a 100 capsule bottle.
: DO NOT exceed 10 GROWTH MAX
J capsules in any 24 hour period.
USA Laboratories makes no representation or warranties concerning the use of GROWTH MAX
Jfor the diagnosis, cure,
mitigation, treatment or prevention of any disease. Seek advice from a health care provider before using this product. *These statements
have not been evaluated by the F.D.A.
1. Greehaff PL, Bodin K, Soderlund K, et al. Effect of oral creatine supplementation on skeletal muscle phospocreatine resynthesis. Am J Physiol 1994;266:E725-30.
2. Greenhaff PL. Creating and its application as an ergogenic aid. Int J Sport Nutr 1995;5:94-101.
3. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci 1992;83:367-74.
4. Green AL, Simpson EJ, Littlewood JJ, et al. Carbohydrate ingestion augments creatine retention during creatine feeding in humans. Acta Physiol Scand 1996;158:195-202.
5. Kreider RB, Ferreira M, Wilson M, et al. Effects of creatine supplementation on body composition, strength, and sprint performance. Med Scri Sports Exerc 1998;30:73-82.
6. Toler SM. Creatine is an ergogen for anaerobic excersise. Nutr Rev 1997;55:21-25.
7. Greenhaff PL. The nutritional biochemistry of creatine. J Nutr Biochem 1997;8:610-18.
8. Mujika I, Padilla S. Creative supplementation as an ergogenic aid for sports performance in highly trained athletes: a creitical review. Int J Sports Med 1997;18:491-96.
9. Grindstaff PD, Kreider R, et al. Effects of creatine supplementation on repetitive sprint performance and body composition in competitive swimmers. Int J Sports Nutr 1997;7:330-46.
10. Peyrebrune MC, Nevill ME, Donaldson FJ, et al. The effects of oral creatine supplementation on performace in single and repeated sprint swinning. J Sports Sci 1998;16:271-79.
11. Balsom PD, Harridge SDR, Soderlund K, et al. Creatine supplementation per de does not enhance endurance exercise performance. Acta Physiol Scand 1993;149:521-23.
12. Stout JR, Eckerson J. Noonan D, et al. The effects of a supplement designed to augment creatine uptake on exercise performance and fat-free mass in football players. Med Scir
Sports Exerc 1997;29:S251.
13. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creating monohydrate patients with mitochondrial cytopathies. Muscle & Nerve 1997;20:1502-9.
14. Sipila I, Rapola J, Simell O, et al. Supllementary creatine as a treatment for gyrate atrophy of the choroid and retina. New Engl J Med 1981;304:867-70.
15. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52:854-7.
16. Andrews R, Greenhaff P, Curtis S, et al. The effect of dietary creatine supplementation of skeleta muscle metabolism in congestive heart failure. Eur Heart J
17. Gordon A, Hultman E, Kaijser L, et al. Creatine supplemenation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res
18. Earnest CP, Almada AL, Mitchell TL. High-performance capillary electrophoresis-pure creatine monohydrate reduces bood lipids in men and women. Clin Sci
19. Hultman E, Soderlund K, Timmons J, et al. Muscle creatine loading in man. J Appl Physicol 1996;81-232-37.
20. Green AL, Hultman E, Macdonald IA, et al. Carbohydrate ingestion augments skeletal muscle creating accumulation during creating supplementation in man. Am J Physiol
21. Feldman EB. Creatine: a dietary supplement and ergogenic aid. Nutr Rev 1999;57:45-50.
22. Vandenberghe K, Gills N, Van Leemputte M, et al. Caffeine counteracts the ergogenic action of muscle creatine loading. J Appl Physiol 1996;80:452-57.
23. Sewell DA, Robinson TM, Casey A, et al. The effect of acute dietary creatine supplementation upto indices of renal, hepatic and haematological function in human subjects. Proc Nutr
24. Poortmans JR, Auquier H. Renaut V, Durussel A, Saugy M, Brisson GR. Effect of short-term creatine supplementation on renal responses in men. Eur J Appl Physico Occup Physiol
25. Earnest C, Almada A, Mitchell T. influence of chronic creatine supplementation on hepatorenal funciton. FASEB J 1996;10:4588.
26. Almada A, Mitchell T, Earnest C. Impact of chronic creatine supplementation on serum enzyme concentrations. FASEB J 1996;10:4567.
27. Koshy KM, Griswold E, Scheneberger EE. Interstitial nephritis in a patient taking creatine. N Engl Med 1999;340:814-5[letter].
28. Pritchard NR, Kaira PA. Renal dysfunction accompanying oral creatine supplements. Lancet 1998;351;1252-53[letter]. Glutamine References:
1. Robinson MK et al. Glutathione deficiency and HIV infection. Lancet 1992;339:1603-4.
2. Grffiths RD. Outcome of critically ill patients after supplementation with glutamine. Nutrition 1997;13:752-54. L-carnitine References:
1. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic effica of propionyl-L-carnitine in patients with congestive heart failure.
2.Giamberardino MA et al. Effects of prolonged L-carnitine adminstration on delayed muscle pain an CK release after eccentric effort. Int J Sports Med 1996;17:320-24.
3. Green RE, Levine AM, Gunning MJ. The effect of L-cartine supplementation on lean body mass male amateur body builders. J AM, Dietet Assoc 1997;(syook):A-72.
4. Murray MT. The many benefits of carnitine. Am J Natural Med 1996;3:6-14 [review].
5. Dal Negro R, Pomari G, et al. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabo and ventilatory response in chronic respiratory insufficiency. Int J Clin Pharmacol
Ther Toxicol 1986;24:453-56.
6. Dal Negro R, Turco P, Pomari C, De Conti F. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1988;26:269-72.
7. Dipalma JR. Carnitine deficiency. Am Family Phys 1988;38:243-51.
8. Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373-90.
9. Del Favero A. Carnitine and gangliosides. Lancet 1988;ii:337 [letter].
10. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure-experimental and clinical study. Jpn Circ J 1992;56:86-94. Cysteine References:
1. Salim AS. Sulfhydryl-containing agents in the treatment of gastric bleeding induced by nonsteroidal anti-inflammatory drugs. Can j Surgery 1993;36:53-58.
2. Droge W, Eck HP, Gander H, Mihm S. Modulation of lymphocyte functions and immune response by cysteine and cysteine derivatives. Am J Med 1991;91(suppl 3C): 140S-44S.
3. Eck HP, Gander H, Hartmann M, et al. Biol Chem Hoppe Seyler 1989;370:101-8.
4. Droge W, Eck HP, Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction--a rationale for treatment with N-acteylcysteine. Immunol Today 1992;13:211-14.
5. Droge W. Cysteine and glutathione deficiency in AIDS patients: A rationale for the treatment with N-acetyl-cysteine. Pharmacol 1993;46:61-65.
6. Kleinveld HA, Demacker PNM, Stalenhoef AFH. Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy sugjects. Eur J Clin Pharmacol 1992;639-42.
7. Olney JW, Ho O-L. Brain damage in infant mice following oral intake of glutamante, aspartate or cysteine. Nature 1970;227:609-10 [letter]. Dhea References:
1. Weksler ME. Hormone replacement for men. Br Med J 1996;312:859-60 [editorial].
2. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994;343:1479-81.
3. Labrie F, Belanger A, Simard J, et al. DHEA and peripheral androgen and estrogen formation: Intracrinology. Ann NY Acad Sci 1995;774:16-28.
4. Reiter WJ, Pycha A, Schatzi G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction a prospective, double-blind randomized, place-bo-controlled study. Urology
5. Diamond P, Cusan L, Gomez J-L, et al. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol
6. Nestler JE, Barlasini CO, Clore JN, et al. Deydroepioandrosterone reduces serum low density lipoprtein levels and body fat but does not alter insulin sensitivity in normal men. J Clin
Endocrinol Metabol 1988;66:57-61.
7. Welle S, Jozefowicz R, Statt M. Failure of DHEA to influence energy and protein metabolism in humans. J Clin Endocrinol Metabol 1990;71:1259.
8. Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of dehydroepiandrosterone in obese men Int J Obesity 1990;14:457-63.
9. Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, et al. Dehydroepiandrosterone in morbidly obesse adolescents: effects on weight, body composition, lipids, and insulin resisitence.
10. Yen Ssc, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. Ann NY Ac Sci 1995;774:128-42.
11. Diamond P, Cusan L, Gomex J-L, et al. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol
12. Mortola J, Yen SSC. The effects of dehydroepiandrosterone on endocrine-metabolic parameters postmenopausal women. J Clin Endocrinol Metabol 1990;71:695-704.
13. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A Biol Sci Med 1997;52:M1-7.
14. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in pysiolgic doses modulates immune function in postmenopausal women. Am J Obstet gynecol
15. Schaefer C, Friedman g, Ettinger B, et al. Dehydroepiandrosterone sulfate (DHEAS), angina, and fatal ischemic heart disease. Am J Epidemiol 1996;14311 suppl):S69 [abstr#274].
16. Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovasculare disease. Ann NY Acad Sci 1995;774:259-70.
17. Jessee RL, Loesser K, et al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann NY Acad Sci 1995;29:281-90.
18. Lahita RG, et al. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987;30:241-48.
19.Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erthematosus with dehyroepiandrosterone: 50 patients treated up to 12 months. J
20. Araghiniknam J, Chung S, Nelson-White T, et al. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sci 1996;59:147-57.
21. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994;343:1479-81.
22. Weinstein RE, Lobocki CA, Gravett S, et al. Decreased adrenal sex steroid in the absence of glucocorticoid suppression in postmenopausal asthmatic women. J Allerg Clin Immunol
23. Wolkowitz OM, Reus VI, Roberts E, et al. Antidepressant and cognition-enhancing effects of DHEA in major depression. Ann NY Acad Sci 1995;774:337-39.
24. Gaby AR. Research review. Nutr Healing Jun 1997: 8. Nutr Healing Jan 1996:7
25. Louviselli A, Pisanu P, Cossu E, et al. Low levels of dehydroepiandrosterone sulfate in adult males with insulin-dependent diabetes melitus. Minerva Endocrinol 1994;19:113-19.
26. Gaby AR. Dehydroepiandrosterone: biological effects and clinical significance. Alt Med Rev 1996;1:60-69 [review].
27. Casson PR, Buster JE. DHEA replacement after menopause: HRT200 or nostrum of the 90's? Contemporary OB/GYN Apr
28. Orner GA et al. Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout. Carcinogensis
29. Metzger C, Mayer D, et al. Sequential appearance and ultrastructure of ampohophillic cell foci, adenomas, and carcinomas in the liver of male and female rats treated with
dehydroepiandrosterone. Taxico Pathol 1995;23:591-605.
30. Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H (A vy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 1979;39:1129-32.
31. McNeil C. Potential drug DHEA hits snags on way to clinic. J Natl Cancer Inst 1997;89:681-83.
32. Jones JA, Nguyen A, Strab M, et al. Use of DHEA in a patient with advanced prostate cancer: a case report and review. Urology 1997;50:784-88.
33. Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone sulfate in women with primary operable breast cancer. Caner Res
34. Skolnick AA. Scientific verdict still out on DHEA. JAMA 1996;276:1365-67 [review].
35. Sahelian R. New supplements and unknown, long-term consequences. Am J Natural Med 1997; [editorial].
36. Casson PR, Santoro N, Elkind-Hirsch, et al. Postmenopausal dehyroepiandrosterone administration increases freee insulin-like growth factor-I and decreases high-density lipoprotein:
a six-month trial. Fertil Steril 1998;70:107-10. Zinc References:
1. Mossad SB, Macknin ML, Medendorp SV, et al. Zinc gluconate lozenges for treating the common cold. Ann Int Med
2. Anonymous. Zinc lozenges reduce the duration of common cold symptoms. Nutr Rev
3. Garland ML, Hagmeyer KO. The role of zinc lozenges in treatment of the common cold. Ann Pharmacother
4. Macknin ML, Piedmonte M, Calendine C, et al. Zinc gluconate lozenges for treating the common cold in children. A randomized controlled trial. JAMA
5. Eby G. Where's the bias? Ann Intern Med
6. Petrus EJ, Lawson KA, Bucci LR, Blum K. Randomized, double-masked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptons in
allergy-tested subjects. Curr Ther Res
7. Weismann K, Jakobsen JP, Weismann JE, et al. Zinc gluconate lozenges for common cold. A double-blind clinical trial. Dan Med Bull
8. Cherry FF, Sandstead HH, Rojas P, et al. Adolescent pregnancy: associations among body weight, zinc nutriture, and pregnancy outcome. Am J Clin Nutr
9. Goldenberg RL, Tamura T, Neggers Y, et al. The effect of zinc supplementation on pregnancy outcome. JAMA
10. Prasad A. Discovery of human zinc deficiency and studies in an experimental human model. Amer clin Nutr
11. Chandra RK. Excessive intake of zinc impairs immune responses. JAMA
12. Bush Al, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A8 amyloid formation by zinc. Science
13. Potocnik FCV, van Rensburg SJ, Park C, et al. Zinc and platelet membrane microviscosity in Alzheimer's disease. S Afr Med J
14. Prasad AS. Zinc in human health: an update. J Trace Elements Exper Med
15. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion-a reversible cause of sideroblastic anemia and bone marrow depression. JAMA
16. Resiser S, et al. Effect of copper intake on blood colesterol and its lipoprotein distribution in men. Nutr Rep Internat
17. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am Jclin Nutr
18. Fischer PWF, Girous A, Labbe MR. Effect of zinc supplementation on copper status in adult man. Am J Clin Nutr
19. Dawson EB, Albers J, McGanity WJ. Serum zinc change due to iron supplementation in teenage pregnancy. Am J Clin Nutr
20. Crofton RW, Gvozdanovic D, Gvozanovic S, et al. Inorganic zinc and the intestinal absorption of ferrous iron. Am J Clin Nutr
21. Argiratos V, Samman S. The effect of calcium carbonate and calcium citrate on the absorption of zinc in healthy female subjects. Eur J Clin Nutr
22. Spence H, Norris C, Williams D. Inhibitory effects of zinc on magnesium balance and magnesium absorption in man. J Am Coll Nutr
23. Brumas V, Hacht B, Filella M, Berthon G. Can N-acetyl-L-cysteine affect zinc metabolisms when used as a paracetamol antidote? Agents Actions
Fifteenth Edition Copyright September, 2005 East End Medical Associates, P.C. International Lyme and Associated DISCLAIMER: The information contained in this monograph is meant for informational purposes only. The management of tick-borne illnesses in any given patient must be approached on an individual basis using the practitioner’s best judgment. TABLE OF CONTENTS
DRUGS TO BE PRESCRIBED IN CERTAIN CIRCUMSTANCES UNDER THE NHS SCHEDULE 2 DRUGS, MEDICINES AND OTHER SUBSTANCES TO BE ORDERED BY CONTRACTORS IN THE PROVISION OF PRIMARY MEDICAL SERVICES UNDER A GENERAL MEDICAL SERVICES CONTRACT ONLY IN CERTAIN CIRCUMSTANCES Drug, medicine or other substance Clobazam Treatment of infections and inflammation of the oropharynx Treatment of